Literature DB >> 12435713

High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients.

Jean-Marc Tréluyer1, Jean-Pierre Morini, Jérome Dimet, Isabelle Gorin, Elisabeth Rey, Jean Deleuze, Pierre-François Ceccaldi, Jean-Paul Escande, Gérard Pons, Nicolas Dupin.   

Abstract

To assess the relationship between antiretroviral drug exposure and lipodystrophy, 69 human immunodeficiency virus type 1-infected patients receiving nelfinavir were investigated cross-sectionally. Lipodystrophy was defined by patients' self-report. Nelfinavir trough concentrations in plasma were significantly related to overall lipodystrophy and peripheral fat wasting scores and appeared to be an independent risk factor for lipodystrophy

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12435713      PMCID： PMC132744          DOI： 10.1128/AAC.46.12.4009-4012.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  Inhibition of adipocyte differentiation by HIV protease inhibitors.

Authors:  B Zhang; K MacNaul; D Szalkowski; Z Li; J Berger; D E Moller
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

2.  Estimation of body fat from skinfold thickness.

Authors:  M A Aboul-Seoud; A L Aboul-Seoud
Journal:  Comput Methods Programs Biomed       Date:  2001-06       Impact factor: 5.428

3.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.

Authors:  A Carr; K Samaras; A Thorisdottir; G R Kaufmann; D J Chisholm; D A Cooper
Journal:  Lancet       Date:  1999-06-19       Impact factor: 79.321

4.  Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations.

Authors:  N Christeff; J C Melchior; P de Truchis; C Perronne; E A Nunez; M L Gougeon
Journal:  AIDS       Date:  1999-11-12       Impact factor: 4.177

5.  Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years.

Authors:  J V Durnin; J Womersley
Journal:  Br J Nutr       Date:  1974-07       Impact factor: 3.718

6.  The metabolic effects, and the composition of the tissue lost, in weight reduction by obese patients on treatment with fenfluramine.

Authors:  J V Durnin; J Womersley
Journal:  Br J Pharmacol       Date:  1973-09       Impact factor: 8.739
  6 in total
  6 in total

1.  High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.

Authors:  Cécile Goujard; Mayeule Legrand; Xavière Panhard; Bertrand Diquet; Xavier Duval; Gilles Peytavin; Isabelle Vincent; Christine Katlama; Catherine Leport; Bénédicte Bonnet; Dominique Salmon-Céron; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.

Authors:  Déborah Hirt; Jean-Marc Treluyer; Vincent Jullien; Ghislaine Firtion; Hélène Chappuy; Elisabeth Rey; Gérard Pons; Laurent Mandelbrot; Saïk Urien
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 3.  Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?

Authors:  Rob E Aarnoutse; Jonathan M Schapiro; Charles A B Boucher; Yechiel A Hekster; David M Burger
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects.

Authors:  Mario Regazzi; Renato Maserati; Paola Villani; Maria Cusato; Patrizia Zucchi; Elena Briganti; Rinaldo Roda; Luca Sacchelli; Francesca Gatti; Palma Delle Foglie; Giulia Nardini; Paolo Fabris; Fernanda Mori; Paula Castelli; Lucia Testa
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 5.  Nelfinavir: a review of its use in the management of HIV infection.

Authors:  Caroline M Perry; James E Frampton; Paul L McCormack; M Asif A Siddiqui; Risto S Cvetković
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children.

Authors:  Déborah Hirt; Saïk Urien; Vincent Jullien; Ghislaine Firtion; Elisabeth Rey; Gérard Pons; Stéphane Blanche; Jean-Marc Treluyer
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.